John Flannery, who is slated to assume the corner office at General Electric in 2018, has served as chief executive of the company’s healthcare division since 2014. There, he helped to turn around GE Healthcare, growing organic revenue by 5% and margins by 100 base points last year.

Under Flannery’s watch, the healthcare unit inked a number of deals, including a development and manufacturing deal with Check-Cap – a company developing an indigestible capsule designed for colorectal screening.

GE Healthcare also partnered with Accuray last year, collaborating on financing options for Accuray’s CyberKnife and TomoTherapy Systems. The deal, which is designed to make it easier for clinicians in Europe to offer the systems, will allow hospitals and healthcare practitioners to lease Accuray equipment and services through a turnkey offering.

In regulatory news, the FDA approved label changes for GE Healthcare’s ultrasound contrast agent, Optison. The decision removed contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection – it’s the first contrast agent available in the U.S. to receive this label change, according to GE.

The company landed a reimbursement win when Cigna revised its coverage to include 3D mammography for routine breast cancer screening. GE Healthcare is one of only two companies with mammography systems on the market in the U.S. that can perform 3D breast tomosynthesis.